We previously developed Cdh23 erl/erl mutant mice (erl mice)
Introduction
Hearing loss has been associated with hair cell loss and the induction of apoptosis [1] . Mutations in the Cadherin 23 (Cdh23) gene may cause hearing loss because they cause the disruption of the inner-ear hair cells during late embryonic/early postnatal development [2, 3] . In hair cells, CDH23 is localized in the tip link, the extracellular filament proposed to gate the mechanotransduction channel [4] . Usher syndrome type 1D (USH1D), autosomal recessive deafness (DFNB12), and certain types of age-related hearing loss (AHL) involve mutations of the Cdh23 gene in humans and mouse models.
One novel recessive mutation erlong (erl is the symbol for the mutation; ERL is the symbol for the mutated protein) of the Cdh23 gene is characterized by progressive hearing loss beginning on postnatal day 27 (P27) [5] . The short interval from normal hearing to deafness (P27-P90) makes this model ideal for screening and validating otoprotective drugs. It was reported that some early-onset hearing-loss patients had CDH23 mutations that had similar phenotypes to the erl mutants [6] , thereby highlighting the importance of studying this mouse model.
Recently, numerous studies have shown that endoplasmic reticulum (ER) stress is involved in neurodegenerative disorders [7, 8] . ER stress is defined as the accumulation of unfolded or misfolded proteins in the ER. The unfolded protein response (UPR) comprises a set of cellular signaling pathways present in mammalian cells that detect unfolded proteins in the ER and direct the protective and/or apoptotic actions that the cell takes [9] . The UPR processes increase the expression of glucose-regulated protein 78 (GRP78/BiP) and CCAAT/enhancer-binding proteinhomologous protein (CHOP) [10] . The upregulation of BiP is commonly used as an ER stress marker. In addition, CHOP, an apoptotic transcriptional factor induced in response to ER stress, is also a popular marker for the assessment of ER stress.
ER stress may also play a role in hearing impairment [11] . Recently, we found that erl mutation leads to hearing loss related to ER stress-induced hair cell apoptosis [12] . Thus, protein-folding errors that are triggered by genetic mutations can be considered the earliest therapeutic target in some genetic hearing disorders. Many anti-ER stress drugs, including chemical chaperones, can be repurposed for otoprotection. In this study, we chose one of the best-characterized chemical chaperones, 4-phenylbutyrate (4PBA), which the US Food and Drug Administration (US FDA) has approved, and which has a good safety profile in humans. We report that 4PBA reduces hearing threshold shifts and hair cell loss in erl mice.
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Materials and methods

Mice
The C57BL/6J (B6) mice and erl mutant mice originally were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). Studies were carried out according to the principles set forth in the Guide for the Care and Use of Laboratory Animals as well as the Institute of Laboratory Animal Resources (protocol 2014-0155). The erl mice were injected intraperitoneally with 4PBA daily (50 mg/kg, dissolved in DMSO, diluted in PBS, ratio 2 : 5; Sigma, Burlington, Massachusetts, USA). The mice in the vehicle group were injected intraperitoneally with equal volume solvent solution. All of the treatments started from postnatal age day 7 to 12 weeks. Also, the untreated group was a group that received no treatment, which acted as a second control.
Immunostaining
The inner ears from B6 mice and erl mutant mice were fixed and decalcified. After they were dehydrated in sucrose and embedded in tissue O.C.T. compound freeze medium (Tissue-Tek, Sakura Finetek, Japan) at − 20°C, the inner ears were sectioned at 5 μm. Sections were stained with anti-CDH23, anti-BiP, or anti-CHOP antibodies. Sample mounts were observed under a fluorescence microscope and read out by LAS X software (Leica DM4500 B; Leica Microsystems Inc., Buffalo Grove, Illinois, USA). The immunofluorescence intensity was analyzed using Image J software (National Institutes of Health, USA) as described previously [13] .
Surface preparation and hair cell counting
The surface preparation was performed as described previously [14] . The surface preparations were stained for F-actin with Alexa Fluor 488-conjugated Phalloidin (Invitrogen, Carlsbad, California, USA) to show hair bundles and DAPI (Invitrogen) was used to stain the nucleus. Immunofluorescent signals were examined using a fluorescence microscope (Leica DM4500B; Leica Microsystems Inc., Wetzlar, Germany).
Auditory brainstem response and distortion product otoacoustic emission testing A computer-aided evoked potential system (IHS3.30; Intelligent Hearing Systems, Miami, Florida, USA) was used as described previously [12] . Briefly, click and 8-, 16-, and 32-kHz tone bursts were channeled through an inserted earphone. The auditory brainstem response (ABR) threshold was identified as the lowest stimulus level at which clear and repeatable waveforms were recognized. The distortion product oto-acoustic emission (DPOAE) measurement was conducted for pure tones at frequencies ranging from 4.4 to 20.3 kHz using the IHS3.30 System (Intelligent Hearing Systems). Frequencies were acquired with the F2 : F1 ratio of 1.22 and with the primary stimulus of 65/55 dB sound pressure level.
Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling staining Apoptotic hair cells were detected by the terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling (TUNEL) assay according to the manufacturer's protocol. The numbers of TUNELpositive cells were counted from three random microscope views from the basal cochlear turns for each animal and the percentage of apoptotic cells was calculated.
Statistical analysis
All values are expressed as the mean SEM. Student's ttest and one-way analysis of variance were used for data analysis using the Statistical Package for the Social Sciences (version 17; SPSS Inc., Chicago, Illinois, USA). A value of P less than 0.05 was considered significant.
Results
CDH23-ERL proteins were retained in the perinuclear cytosol area in the OHC of erl mice
We first examined CDH23 protein localization in the innerear cryosections of B6 mice and erl mice at P6. B6 mice showed a CDH23 protein signal at the top of the outer hair cells (OHCs) (asterisks, Fig. 1a) . Instead, erl mice showed a striking redistribution of CDH23 with an enriched signal in the cytoplasm moving in the direction of the hair bundles. Anti-CDH23 and anti-BiP were used to co-stain the innerear cryosections of erl mice at P12. OHCs were heavily stained for CDH23 and BiP (Fig. 1b) , whereas the ampulla of the vestibular was not stained as heavily (Fig. 1c) . This may explain why CDH23-ERL affects hearing, but not the vestibular function.
4PBA prevents hearing loss in erl mice CDH23-ERL protein retention in the ER decreased the migration of this protein to the tip links. We hypothesized that the unfolded or misfolded CDH23-ERL protein may induce ER stress and UPR in the hair cells of erl mice. We used 4PBA, a chemical chaperone, and an ER stress inhibitor to test whether 4PBA could have an otoprotection effect in erl mice. For the erl mice in the Data are presented as mean SEM (*P < 0.05, **P < 0.001, n = 6/ group, one-way ANOVA). (b) The distortion product oto-acoustic emission (DPOAE) amplitudes in the untreated, vehicle, and 4PBA groups were measured at 12 weeks at different F2 frequencies. 4PBA group showed higher DPOAE amplitudes at high frequencies. Data are presented as mean SEM (*P < 0.05, n = 6/group, one-way ANOVA). See also Supplementary Fig. 1 (Supplemental digital content 1, http:// links.lww.com/WNR/A498). ANOVA, analysis of variance. untreated, vehicle, and 4PBA groups, ABR and DPOAE were measured (Fig. 2a and b) . The ABR thresholds in the 4PBA group were significantly lower than those in the vehicle group or the untreated group for click, 8-, 16-, and 32-kHz stimulus frequencies at the ages of 6, 8, and 12 weeks (Fig. 2a) . DPOAE amplitudes in the 4PBA group at high frequencies were significantly higher than those of the vehicle group and the untreated group at 12 weeks (Fig. 2b) , but not at 4, 6, or 8 weeks ( Supplementary Fig. 1a , Supplemental digital content 1, http://links.lww.com/WNR/A498).
4PBA protects against hair cell loss and apoptosis in erl mice OHC loss was observed in the apex, middle, and basal turns of the cochleae in the vehicle group at 10 weeks. In the 4PBA group, only a small amount of OHC loss was observed in the apex, middle, and basal turns (Fig. 3a) . The mean percentage of OHC loss in the apex, middle, and basal turns of the cochleae was significantly lower in the 4PBA group than in the vehicle group. We then applied TUNEL staining in the vehicle and 4PBA groups at 6 weeks (Fig. 3b) . In the basal turns of the cochleae, the vehicle group showed more TUNELpositive OHCs than it did in the 4PBA group.
4PBA downregulated ER stress-associated proteins in erl mice
To investigate ER stress-associated proteins in situ in erl mice and to determine whether 4PBA could suppress ER stress in this mouse model, we stained the erl mice tissue section with BiP and CHOP antibody in the vehicle and 4PBA groups at P30 (Fig. 4a and b) . The results showed that the BiP and CHOP signals in the OHCs in the 4PBA group were significantly decreased compared with the vehicle group. Therefore, ER stress-related proteins were downregulated after the 4PBA treatment.
Discussion
Hair cell loss in erl mice involves apoptosis as hearing is protected up to 30 dB with antiapoptotic drugs [5, 15] . Our results indicate that the erl mutation causes the mutant CDH23-ERL protein to accumulate in the ER, which then triggers the UPR. If the UPR cannot handle the accumulation (or overproduction) of the mutant CDH23-ERL, it switches to ER stress and then induces apoptosis.
The ER organization is well developed and specialized in the OHCs. The ER system in the OHCs includes apical cistern, subsurface cistern, Hensen's body, and subsynaptic cistern [16] . OHCs contain these membranous organelles that may contribute to mechanoelectrical transduction [17] . Impaired ER function in the OHCs may influence some molecular machinery, for instance, protein folding.
In this study, we provided direct in-vivo morphological evidence of protein accumulation related to ER stress causing hearing loss in a mammalian model of USH1D or DFNB12. This opens a preventive time window targeted at an upstream pathway leading to apoptosis in mammals. In this study, only cochlear hair cells, not vestibular hair cells, were affected. This explains why the erl mice had only hearing loss without balance defects, representing normal vestibular function. The reason why it only affects cochlear hair cells warrants further studies.
The major function of 4PBA is to scavenge for ammonia and glutamine. The US FDA has approved 4PBA to treat urea cycle disorders, which are genetic diseases in which nitrogen waste builds up in the blood plasma as ammonia glutamine [18] . 4PBA is supposed to interact with the hydrophobic domains of misfolded proteins and thus prevent their aggregation, thereby reducing ER stress. 4PBA may stabilize the CDH23-ERL mutant protein in the ER, allowing it to reach the tip link to perform normal functions at younger ages.
4PBA may potentially be used to treat neurologic diseases because it goes through the blood-brain barrier, and it shows significant neuroprotective effects in mouse models of neurodegenerative diseases [19, 20] . In our study, 4PBA may cross the blood-labyrinth barrier, a barrier between the blood and the inner-ear fluids, to enter hair cells, attenuate ER stress, and facilitate the migration of the CDH23-ERL mutant protein in the ER, allowing it to form the tip link to perform normal functions and thus protect hearing loss.
Conclusion
Our studies on the erl mutation in Cdh23 mutant mice showed that 4PBA exerts an otoprotective effect, which provides the potential to repurpose the FDA-approved drug. Through this study, we hope to provide new targets for exploring preventive therapies for hearing loss.
